Lipocine (LPCN) Expected to Announce Earnings on Thursday

Lipocine (NASDAQ:LPCN) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $0.1160 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 9:30 AM ET.

Lipocine Price Performance

NASDAQ LPCN opened at $8.43 on Thursday. The stock’s 50 day simple moving average is $8.89 and its 200 day simple moving average is $5.11. Lipocine has a one year low of $2.52 and a one year high of $12.37. The firm has a market cap of $46.79 million, a PE ratio of -8.26 and a beta of 0.98.

Institutional Investors Weigh In On Lipocine

A number of institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC bought a new position in shares of Lipocine during the 4th quarter valued at about $1,602,000. Squadron Capital Management LLC bought a new stake in Lipocine during the 4th quarter worth approximately $4,256,000. Boothbay Fund Management LLC acquired a new stake in Lipocine during the 4th quarter worth approximately $441,000. Diadema Partners LP bought a new position in Lipocine in the fourth quarter valued at approximately $2,095,000. Finally, Jane Street Group LLC acquired a new position in shares of Lipocine in the fourth quarter valued at approximately $85,000. 9.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LPCN has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, February 15th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.